Pelacarsen, olpasiran, zerlasiran, and lepodisiran

1 paper1 finding

Outcomes

1

Lipoprotein

downin humans1

1 study

Pelacarsen, olpasiran, zerlasiran, and lepodisiran decreases lipoprotein in humans (79% to approximately 97% placebo-adjusted reductions).
“Phase 2 data demonstrate Lp(a) reductions ranging from 79% to approximately 97% on a placebo-adjusted basis”
ReviewPhase 2 trials; placebo-adjusted reductions
RNA-Based Therapies for Lipoprotein(a) Reduction: Antisense Oligonucleotides, Small Interfering RNAs, and Emerging Platforms
Current atherosclerosis reports14 Oct 2026

More on Lipoprotein

Latest

1 in 12 months

Current Atherosclerosis Reports14 Oct

RNA-Based Therapies for Lipoprotein(a) Reduction: Antisense Oligonucleotides, Small Interfering RNAs, and Emerging Platforms

ReviewInterventions